Cancer Drugs
Libtayo
Also known as: Cemiplimab, Anti-PD-1
Definition
Cemiplimab, a PD-1 inhibitor approved for cutaneous squamous cell carcinoma and advanced NSCLC with high PD-L1 expression.
Detailed Explanation
Libtayo blocks PD-1 to enhance T-cell activity. It is an alternative to Keytruda or OPDIVO in select settings and is often used when PD-L1 expression is high.